Cell signaling inhibitors
US5470878A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 8, 1993 |
| Grant date | Nov 28, 1995 |
| Priority date | — |
| Expiry date | Dec 8, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Therapeutic compounds have the formula: EQU (X)j-(non-cyclic core moiety), j being an integer from one to three, the core moiety is non-cyclic and X is a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.